Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 5Kidney Neoplasms 5von Hippel-Lindau Disease 4Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 9Nivolumab 9Ipilimumab 7cabozantinib 6CTLA-4 Antigen 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 4Axitinib 4lenvatinib 2fludarabine 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1belzutifan 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Nephrectomy 1Metastasectomy 1Inulin 1Immunoglobulin G 1Ibandronic Acid 1Hyaluronoglucosaminidase 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × belzutifan × 1 year × Clear all
NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

NYU Langone Health

Phase 1 Recruiting
12 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡